Angiogenesis Modulators

Publication Date	January 2008
Publisher	RI Technologies
Product Type	Report
Pages	161
ISBN Number	not applicable
Product Code	RIT00006

Price

£1,425.00
approximately: $2,800 | €1,812

PDF

Order above formats by FAX

Summary

This market insight report on Angiogenesis Modulators studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care.

The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. The study includes estimates and projections for the total global angiogenesis therapeutic products market. Projections and estimates are also illustrated by geographic regions encompassing United States, Europe, Asia-Pacific and Rest of World. Business profiles of 34 major companies are discussed in the report.

The report serves as a guide to global angiogenesis industry covering 325 companies engaged in angiogenesis research, testing and supply of products and services. Major Contract Research Organizations and Universities serving angiogenesis industry are also covered in the Corporate Directory section of this report. Information related product developments, partnerships, collaborations, and mergers and acquisitions are also covered in the report featuring 95 graphically represented exclusive exhibits.

Content

I. Scope And Methodology
II. Report Synopsis
- 1. Introduction
  - Angiogenesis
  - Segmentation of Angiogenesis
  - Exhibit 1: Segmentation of Global Angiogenesis Therapeutic Products Market by Angiogenesis Modulators (Inhibitors and Stimulators) and Therapeutic Areas (Cancer, Cardiovascular and Other)
- 2. Global Market Analysis
  - Exhibit 2: Angiogenesis Therapeutic Products (2005-2011) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- 3. Angiogenesis Modulators Analysis by Geographic Region
  - Inhibitors
  - Exhibit 3: Angiogenesis Inhibitors (2005-2011) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 4: Angiogenesis Inhibitors (2005, 2008 and 2011) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
  - Stimulators
  - Exhibit 5: Angiogenesis Stimulators (2005-2011) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 6: Angiogenesis Stimulators (2005, 2008 and 2011) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World6
  - Analysis of Angiogenesis Disease Area by Geographic Region.
  - Cancer
  - Exhibit 7: Angiogenesis Therapeutic Products for Cancer (2005-2011) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million
  - Exhibit 8: Angiogenesis Therapeutic Products for Cancer (2005, 2008 and 2011) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World
  - Cardiovascular
  - Exhibit 9: Angiogenesis Therapeutic Products for Cardiovascular Diseases (2005-2011) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million
  - Exhibit 10: Angiogenesis Therapeutic Products for Cardiovascular Diseases (2005, 2008 and 2011) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World
  - Other
  - Exhibit 11: Angiogenesis Therapeutic Products for Other Angiogenesis Based Diseases (2005-2011) - Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 12: Angiogenesis Therapeutic Products for Other Angiogenesis Based Diseases(2005, 2008 and 2011) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World
  - Exhibit 13: List of Major Global Companies
- 4. Regional Market Analysis
  - The United States
  - Exhibit 14: Angiogenesis Therapeutic Products (2005-2011) - United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Major Companies in the United States
  - Abbott Laboratories
  - Adnexus Therapeutics, Inc.
  - Alcon, Inc.
  - Amgen, Inc.
  - ...ngstrom Pharmaceuticals, Inc.
  - Callisto Pharmaceuticals, Inc.
  - Cardium Therapeutics, Inc.
  - Celgene Corporation
  - Collagenex Pharmaceuticals, Inc.
  - Corautus Genetics, Inc.
  - Eisai, Inc.
  - Entremed, Inc.
  - Genaera Corporation
  - Genentech, Inc.
  - Genvec, Inc.
  - Genzyme Corporation
  - Human Genome Sciences, Inc.
  - Imclone Systems, Inc.
  - Intradigm Corporation
  - OSI Pharmaceuticals, Inc.
  - Oxigene, Inc.
  - Pfizer, Inc.
  - Sirna Therapeutics, Inc.
  - The US Market Analysis by Type of Angiogenesis Modulators
  - Exhibit 15: Angiogenesis Therapeutic Products (2005-2011) - United States Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included)
  - Exhibit 16: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of United States Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included)
  - Europe
  - Exhibit 17: Angiogenesis Therapeutic Products (2005-2011) - European Analysis (Current & Future) in US$ Million (Graphical Representation Included)
  - Major Companies in Europe
  - Antisoma plc (UK)
  - Astrazeneca plc (UK)
  - Bayer Healthcare AG (Germany)
  - F.Hoffmann-La Roche Ltd. (Switzerland)
  - Merck KGaA(Germany)
  - Novartis AG (Switzerland)
  - UCB SA (Belgium)
  - Angiogenesis Modulators Analysis by Geographic Region
  - Inhibitors
  - Exhibit 18: Angiogenesis Inhibitors (2005-2011) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 19: Angiogenesis Inhibitors (2005, 2008 and 2011) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe (Graphical Representation Included)
  - Stimulators
  - Exhibit 20: Angiogenesis Stimulators (2005-2011) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe in US$ Million (Graphical Representation Included)
  - Exhibit 21: Angiogenesis Stimulators (2005, 2008 and 2011) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe
  - Asia-Pacific
  - Exhibit 22: Angiogenesis Therapeutic Products (2005-2011) - Asia-Pacific Market Analysis(Current & Future) in US$ Million (Graphical Representation Included)
  - Major Companies in Asia-Pacific
  - Chugai Pharmaceutical Co., Ltd. (Japan)
  - Progen Industries Ltd. (Australia)
  - Angiogenesis Modulators Analysis by Geographic Region
  - Inhibitors
  - Exhibit 23: Angiogenesis Inhibitors (2005-2011) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 24: Angiogenesis Inhibitors (2005, 2008 and 2011) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (Graphical Representation Included)
  - Stimulators
  - Exhibit 25: Angiogenesis Stimulators (2005-2011) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
  - Exhibit 26: Angiogenesis Stimulators (2005, 2008 and 2011) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (Graphical Representation Included)
  - Rest of World
  - Exhibit 27: Angiogenesis Therapeutic Products (2005-2011) - Rest of World Market Analysis(Current & Future) in US$ Million (Graphical Representation Included)
  - Angiogenesis Modulators Analysis by Geographic Region
  - Inhibitors
  - Exhibit 28: Angiogenesis Inhibitors (2005-2011) - Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other in US$ Million (Graphical Representation Included)
  - Exhibit 29: Angiogenesis Inhibitors (2005, 2008 and 2011) - Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (Graphical Representation Included)
  - Stimulators
  - Exhibit 30: Angiogenesis Stimulators (2005-2011) - Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other in US$ Million (Graphical Representation Included)
  - Exhibit 31: Angiogenesis Stimulators (2005, 2008 and 2011) - Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (Graphical Representation Included)
III. Product Research
- 1. Introduction
  - Angiogenesis - The Growth of New Blood Vessels
  - Global Growth Trends - Angiogenesis Therapeutic Products
  - Exhibit 32: Global Market for Angiogenesis Therapeutic Products: Geographic Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
  - The Process
  - The Types
  - Sprouting Angiogenesis
  - Role of Angioprotien in Sprouting of Angiogenesis
  - Intussusceptive Angiogenesis
  - Role of Intussusceptive Angiogenesis in Embryonic Vascular Network Configuration
  - Therapeutic Angiogenesis
  - Role of Therapeutic Angiogenesis in Various Diseases
  - Delivery of Drugs in Cancer Therapy through Angiogenesis
  - How Angiogenic Therapy Differs from Traditional Therapy?
- 2. Modulators of Angiogenesis
  - Growth Trends - Global Angiogenesis Therapeutic Products by Modulators
  - Exhibit 33: Global Market for Angiogenesis Therapeutic Products: Angiogenesis Modulators (Inhibitors and Stimulators) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
  - 2.1 Angiogenesis Inhibitors
    - Growth Trends - Global Market for Angiogenesis Inhibitors
    - Exhibit 34: Global Market for Angiogenesis Inhibitors: Geographic Regions (Asia-Pacific, Europe, Japan, Canada, United States) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
    - Natural Angiogenesis Inhibitors
    - Angiostatin - A Potent Angiogenesis Inhibitor of Tumor Growth
    - Heparin Hexasaccharide Fragment
    - Interleukin-12
    - Placental Ribonuclease Inhibitor
    - Retinoids
    - Thrombospondin-1 (TSP-1)
    - Role of TSP-1 as Autocrine Negative Regulator for Human Dendritic Cell Activation
    - Cartilage Derived Inhibitor
    - Angioarrestin
    - Endostatin
    - Platelet Factor-4
    - Metalloproteinase Inhibitors
    - Interferon Alpha/Beta/Gamma
    - Other
  - 2.2 Angiogenesis Stimulators
    - Growth Trends - Global Market for Angiogenesis Stimulators
    - Exhibit 35: Global Market for Angiogenesis Stimulators: Geographic Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
    - Natural Angiogenic Stimulators
    - Vascular Endothelial Growth Factor
    - VEGF Splice Variants and Their Functions
    - Role of VEGF in Various Diseases
    - Effect of VEGF & bFGF on In-vivo and In-vitro Conditions
    - Fibroblast Growth Factors
    - Basic FGF
    - Expression of bFGF (FGF2) in Various Diseases
    - Alzheimer's
    - Precursor Neural Cells of Mice
    - Acidic FGF
    - Role of aFGF in ADPKD
    - Expression of aFGF in Alzheimer's
    - Granulocyte Colony-Stimulating Factor
    - Impact of G-CSF on Neutrophils
    - The USAge of G-CSF in Pharma Industry
    - Angiogenin
    - Angiopoietin-1
    - Platelet Derived Endothelial Cell Growth Factor
    - Uterine Cervical Cancers and Role of PD-ECGF
    - Leptin
    - Leptin€s MoA
    - Midkine
    - Placental Growth Factor
    - Stimulation of Inflammation and Swelling - A Role of Placental Growth Factor
    - Hepatocyte Growth Factor (HGF)/Scatter Factor (SF)
    - Transforming Growth Factor (TGF)
    - TGFa
    - TGF
    - The TGF receptor
    - Other
- 3. Angiogenesis in Diseases
  - Growth Trends - Global Market for Angiogenesis Therapeutic Areas
  - Exhibit 36: Global Market for Angiogenesis Therapeutic Products: Major Angiogenesis Therapeutic Areas (Cardiovascular Disorders, Other* and Cancer) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
  - 3.1 Remedy of Diseases with Angiogenesis Inhibitors
    - Cancer
    - Cancer Therapy - Role of Angiogenesis
    - Global Market for Major Cancer Types
    - Exhibit 37: Major Cancer Types (2005 & 2006): Global Market for Major Cancer Types - Breast, Colorectal, Lung and Prostate in US$ Million (Graphical Representation Included)
    - Growth Trends - Global Market for Angiogenesis Therapeutic Products for Cancer
    - Exhibit 38: Global Market for Angiogenesis Therapeutic Products for Cancer: Geographic Regions Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
    - Cancer Therapy Angiogenesis Vs Conventional
    - Conventional Cancer Treatments
    - Surgery
    - Radiation Therapy for Healing Cancer
    - Chemotherapy Treatment
    - Hormone Stimulation Therapy
    - Process of Immuno Therapy
    - Targeted Therapy
    - Angiostatic Therapy
    - Angiostatic Agents
    - Angiolytic Photodynamic Therapy
    - Researches in Development of Cancer Therapy
    - Angiobalans
    - Global Cancer Demographics
    - Exhibit 39: Cancer Incidents (2006, 2010 & 2020): Estimates and Projections for Global Cancer Incidents in Million/Year with Mortality Percentage (Graphical Representation Included)
    - Alzheimer€s
    - Dermatology
    - Cosmetic Dermatology
    - Angiogenesis in Dermatology
    - Angiogenesis Inhibitor
    - Angiogenesis Stimulating Drugs
    - Psoriasis
    - Rosacea
    - MoA of Photoaging in Rosacea Pathogenesis
    - Ophthalmology
    - Age Related Macular Degeneration
    - Advanced stage of vision loss
    - Causes
    - Characteristics of the disorder
    - Detection process of the Disorder
    - Medication
    - Precautionary measure
    - Types of AMD
    - Non-Neo-vascular (dry) AMD
    - Neo-vascular (wet) AMD
    - Other Turmoil Based on Angiogenesis
    - Rubeosis Iridis
    - Neovascularization
    - Neovascularization in Association with Angiogenesis
    - Rheumatology
    - Rheumatoid Arthritis
    - Angiogenesis in Rheumatoid Arthritis - Pathogenic and Therapeutic Implications
    - Osteoarthritis (OA), Angiogenesis and Inflammation
    - Other
    - Inflammatory Diseases
    - Growth of New Blood Vessels in Inflammation
    - Cause of joint swelling due to inflammation
    - Endometriosis
    - Symptoms of the Disease
  - 3.2 Remedy of Diseases with Angiogenesis Stimulators
    - Wound Care - Role of Angiogenesis
    - Soluble Factors Responsible for Wound Angiogenesis
    - Diabetic Foot Ulcers
    - Angiogenesis in Cardiovascular Disorders
    - Growth Trends - Global Market for Angiogenesis Therapeutic Products for
    - Cardiovascular Disorders
    - Exhibit 40: Global Market for Angiogenesis Therapeutic Products for Cardiovascular Disorders: Geographic Regions (United States, Asia-Pacific and Europe) Ranked by Projected CAGR for 2005 through 2011 (Graphical Representation Included)
    - Ischemia
    - Role of ASK 1 in Angiogenesis during Ischemia
    - Role of NGF in Neo-Vascularization during Ischemic Conditions
    - Congestive Heart Failure
    - Root of CHF
    - Detection of CHF
    - Treatment of CHF
    - Role of Angiogenesis in CHF
    - Coronary Artery Disease
    - Angina
    - Heart Attack
    - Heart Failures
    - Arrhythmias
    - Symptoms Identified for CAD
    - Role of Angiogenesis in CAD Treatment
    - Peripheral Vascular Disease
    - Angiogenic Therapy for the Treatment of PVD
    - Peripheral Artery Disease
    - Therapeutic Angiogenesis in PAD
    - Myocardial Infarction
    - Treatment of Myocardial Infarction Using Non-Invasive Imaging of Myocardial Angiogenesis
IV. Market Dynamics
- 1. Market Overview
  - Global Market Analysis
  - Exhibit 41: Angiogenesis Therapeutic Products (2005-2011) - Global Market Analysis(Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
  - Exhibit 42: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
- 2. Major Companies in Angiogenesis Industry
  - Abbott Laboratories (USA)
  - Adnexus Therapeutics, Inc. (USA)
  - Aeterna Zentaris, Inc. (Canada)
  - Alcon, Inc. (USA)
  - Amgen, Inc. (USA)
  - Angiotech Pharmaceuticals, Inc. (Canada)
  - ...ngstrom Pharmaceuticals, Inc. (USA)
  - Antisoma plc (UK)
  - Astrazeneca plc (UK)
  - Bayer Healthcare AG (Germany)
  - Callisto Pharmaceuticals, Inc. (USA)
  - Cardium Therapeutics, Inc. (USA)
  - Celgene Corporation (USA)
  - Chugai Pharmaceutical Co., Ltd. (Japan)
  - Collagenex Pharmaceuticals, Inc. (USA)
  - Corautus Genetics, Inc. (USA)
  - Eisai, Inc. (USA)
  - Entremed, Inc. (USA)
  - F.Hoffmann-La Roche Ltd. (Switzerland)
  - Genaera Corporation (USA)
  - Genentech, Inc. (USA)
  - Genvec, Inc. (USA)
  - Genzyme Corporation (USA)
  - Human Genome Sciences, Inc. (USA)
  - Imclone Systems, Inc. (USA)
  - Intradigm Corporation (USA)
  - Merck KGaA (Germany)
  - Novartis AG (Switzerland)
  - OSI Pharmaceuticals, Inc. (USA)
  - Oxigene, Inc. (USA)
  - Pfizer, Inc. (USA)
  - Progen Industries Ltd. (Australia)
  - Sirna Therapeutics, Inc. (USA)
  - TAP Pharmaceutical Products, Inc. (USA)
  - UCB SA (Belgium)
- 3. Recent Activities in Angiogenesis Industry
  - Johnson & Johnson Acquires Pfizer€s Consumer Healthcare Business
  - Celgene Acquires API Unit from Siegfried Ltd.
  - Otsuka and Chugai in Co-Promotion Deal
  - Genetix Acquires Applied Imaging Corporation
  - InterMune and Roche Close Collaboration Agreement
  - EntreMed Presents 2ME2 for Rheumatoid Arthritis
  - Genentech to Acquire Tanox
  - Biomira Acquires ProlX Pharmaceuticals
  - Genzyme to Acquire AnorMED
  - Pfizer to Acquire PowderMed
  - CTT Cancer Targeting Technologies and Karyon Ltd., to Merge
  - Valentis and Urigen in Merger Deal
  - LibraGen and Sanofi-Aventis in Partnership for Microbial Diversity Applications
  - Schering and Sonus Sign Global Licensing Agreement for TOCOSOL(R) Paclitaxel
  - Merck Acquires Serono
  - Sangamo to Acquire Edwards' Angiogenesis Program
  - AstraZeneca Acquires Cambridge Antibody Technology
  - GSK and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor
  - Cardium Acquires Wound Healing Technology and Related Assets of TRC
  - GSK and Galapagos Enter Into an Alliance for Osteoarthritis Drug Development
  - Caliper Acquires Xenogen
  - Pharmacopeia and Allergan Inc., in AMD Research Agreement
  - Angiotech Pharmaceuticals Acquires Quill Medical Inc.
  - Mayne Acquires SuperGen's North American Rights for Oncology Products
  - Erbitux Approved in the US
  - Corgentech Adopts New Name
  - Angiotech and Genzyme Enter Into Strategic Collaboration for Developing Oncology Treatments
  - Alcon and Amgen to Jointly Develop Ophthalmology Therapies
  - CancerVax Merges with Micromet
  - Microbix and Angiogen Enter Into Marketing Agreement
  - SuperGen Acquires Montigen
  - Novartis Takes Over Chiron
  - Amgen Completes Acquisition of Abgenix
  - AEterna Zentaris€ Development of Cetrorelix to Continue In Japan
  - Corautus Genetics Puts Forth VEGF-2 Studies
  - Angiotech Pharmaceuticals Takes Over American Medical Instruments
  - Amgen and Biovitrum in License Agreement
  - Cryptome Takes Over HealthLinx
  - AngioGenex Merges with eClic
  - Merck Acquires Full US Rights to BLP25 Liposome Vaccine from Biomira
  - Human Genome Science and Amgen in Licensing Agreement
  - Protein Design Labs Changes Corporate Identity
  - Bausch & Lomb and PTC Therapeutics in Research Collaboration Deal
  - Sanofi-Aventis and Regeneron Pharmaceuticals Amend VEGF Collaboration
  - OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals
  - Hybridon Adopts New Name
  - Xencor and Centocor in Monoclonal Antibodies Agreement
  - Corautus in Diabetic Neuropathy Licensing Agreement
  - Xantos and Cryptome Sign Agreement to Validate Cancer Leads
  - Xantos and Atugen Sign Collaboration Agreement
  - Allergan and Sanwa Kagaku Kenkyusho to Develop Posurdex in Japan
  - Corautus and Boehringer Ingelheim Sign Agreement to Produce VEGF-2
  - Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006)
  - 7TM Signs Therapeutic Angiogenesis Research Agreement with P&G
  - Genzyme Acquires Verigen
  - Antisoma and Raylo Sign Agreement for Manufacturing AS1411
  - Johnson & Johnson Acquires Closure Medical Corp.
  - Alcon and Morphochem Enter Into Alliance for Ophthalmic Compounds
  - ImClone Systems Signs License Agreements
  - Pfizer Takes Over Angiosyn
  - Genzyme Acquires ILEX Oncology
  - EPIX Medical Changes name to EPIX Pharmaceuticals
  - terna Laboratories Changes Corporate Identity
  - UCB SA Takes Over Celltech Group plc
  - Compound Therapeutics Acquires Phylos
  - Chiron and XOMA in Collaboration Agreement
  - Thrombogenics and Geymonat SpA for PIGF Development
  - Eli Lilly Acquires Applied Molecular Evolution
- 4. Regional Market Analysis
  - A. The United States
    - Market Analysis
    - Cancer Incidents in the United States
    - Exhibit 43: Cancer Incidents and Percentage of Deaths in the United States in 2005 and 2006
    - Exhibit 44: US Cancer Incidents (2006): No. of Cases by Type of Cancer - Prostate, Breast, Lung, Colorectal and Other (Graphical Representation Included)
    - US Market for Interventional Peripheral Vascular Products
    - Exhibit 45: Interventional Peripheral Vascular Products (2005 & 2010) - The US Market Analysis in US$ Million
    - Analysis by Type of Angiogenesis Modulators
    - Exhibit 46: Angiogenesis Therapeutic Products (2005-2011) - United States Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included)
    - Exhibit 47: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of United States Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included)
    - Analysis by Disease Area
    - Exhibit 48: Angiogenesis Therapeutic Products (2005-2011) - United States Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included)
    - Exhibit 49: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of United States Market Value by Disease Area for Cancer, Cardiovascular and Other
    - Exhibit 50: List of Major Companies in the United States
  - B. Europe
    - Market Analysis
    - Exhibit 51: Angiogenesis Therapeutic Products (2005-2011) - European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
    - Analysis by Geographic Region
    - Exhibit 52: Angiogenesis Therapeutic Products (2005-2011) - European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France Switzerland, and Rest of Europe in US$ Million (Graphical Representation Included)
    - Exhibit 53: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France Switzerland, and Rest of Europe
    - Analysis by Type of Angiogenesis Modulators
    - Exhibit 54: Angiogenesis Therapeutic Products (2005-2011) - European Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included)
    - Exhibit 55: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of European Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included)
    - Analysis by Disease Area
    - Exhibit 56: Angiogenesis Therapeutic Products (2005-2011) - European Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included)
    - Exhibit 57: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of European Market Value by Disease Area for Cancer, Cardiovascular and Other
    - Exhibit 58: List of Major Companies in Europe
    - European Angiogenesis Modulators Market by Country
    - B1. Germany
    - B2. The United Kingdom
    - B3. France
    - B4. Switzerland
    - B5. Rest of Europe
  - C. Asia-Pacific
    - Market Analysis
    - Exhibit 69: Angiogenesis Therapeutic Products (2005-2011) - Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
    - Analysis by Geographic Region
    - Exhibit 70: Angiogenesis Therapeutic Products (2005-2011) - Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
    - Exhibit 71: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (Graphical Representation Included)
    - Analysis by Angiogenesis Modulators
    - Exhibit 72: Angiogenesis Therapeutic Products (2005-2011) - Asia-Pacific Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included)
    - Exhibit 73: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Asia-Pacific Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included)
    - Analysis by Disease Area
    - Exhibit 74: Angiogenesis Therapeutic Products (2005-2011) - Asia-Pacific Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included)
    - Exhibit 75: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Asia-Pacific Market Value by Disease Area for Cancer, Cardiovascular and Other
    - Exhibit 76: List of Major Companies in Asia-Pacific
    - Asia-Pacific Angiogenesis Modulators Market by Country
    - C1. Japan
    - C2. Rest of Asia-Pacific
  - D. Rest of World
    - Market Analysis
    - Exhibit 81: Angiogenesis Therapeutic Products (2005-2011) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
    - Analysis by Geographic Region
    - Exhibit 82: Angiogenesis Therapeutic Products (2005-2011) - Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other in US$ Million (Graphical Representation Included)
    - Exhibit 83: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (Graphical Representation Included)
    - Analysis by Angiogenesis Modulators
    - Exhibit 84: Angiogenesis Therapeutic Products (2005-2011) - Rest of World Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included)
    - Exhibit 85: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Rest of World Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included)
    - Analysis by Disease Area
    - Exhibit 86: Angiogenesis Therapeutic Products (2005-2011) - Rest of World Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included)
    - Exhibit 87: Angiogenesis Therapeutic Products (2005, 2008 and 2011) - Percentage Breakdown of Rest of World Market Value by Disease Area for Cancer, Cardiovascular and Other
    - Rest of World Angiogenesis Market by Region
    - D1. Latin America
    - D2. Rest of World (Excluding Latin America)
- V. Corporate Directory